Arbutus Biopharma Corporation (NASDAQ: ABUS): Hunting Genuine Value In Market Debris


Morgan Stanley & Co. LLC recently announced the acquisition of new stake in Arbutus Biopharma Corporation (NASDAQ:ABUS). The institutional investor has increased its shareholding in the Healthcare company by 4.13% to 3.49 million shares with purchase of 0.14 million shares. This fresh investment now brings its stake to 5.06% valued currently at $13.3 million. In addition, The Vanguard Group, Inc. raised its holdings by 0.69 million to 1.8 million shares. And Hudson Bay Capital Management LP has lifted its position by 21.88% or 0.17 million shares – to 0.97 million shares.

With over 2.4 million Arbutus Biopharma Corporation (ABUS) shares trading Friday and a closing price of $3.18 on the day, the dollar volume was approximately $7.62 million. The shares have shown a negative weekly performance of -8.36% and its price on 08/21/20 lost nearly -4.79%. Currently, there are 69.61M common shares owned by the public and among those 60.15M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for ABUS have a consensus price objective of $6.00. The analysts have set the share’s price value over the next 12 months at a high of $8.00 and a low of $4.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Arbutus Biopharma Corporation stock is 2.30 for the next 12 months. The average price target is 38.49% above its last price level and an upside to the estimated low will see the stock gain 20.5% over that period. But an upside of 60.25% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.

Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 20,000 shares.

The top 3 mutual fund holders in Arbutus Biopharma Corporation are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and PRIMECAP Odyssey Aggressive Growt. Vanguard Total Stock Market Index owns 1.15 million shares of the company’s stock, all valued at over $4.38 million. The company bought an additional 0.12 million shares recently to bring their total holdings to about 1.67% of the shares outstanding. Vanguard Extended Market Index Fu sold 82693.0 shares to see its total holdings shrink to 0.6 million shares valued at over $2.3 million and representing 0.88% of the shares outstanding. PRIMECAP Odyssey Aggressive Growt sold 80100.0 shares to bring its total holdings to over 0.5 million shares at a value of $1.91 million. PRIMECAP Odyssey Aggressive Growt now owns shares totaling to 0.73% of the shares outstanding.

Shares of Arbutus Biopharma Corporation (NASDAQ: ABUS) opened at $3.33, down -$0.01 from a prior closing price of $3.34. However, the script later closed the day at $3.18, down -4.79%. The company’s stock has a 5-day price change of -8.36% and 38.86% over the past three months. ABUS shares are trading 14.39% year to date (YTD), with the 12-month market performance up to 117.81% higher. It has a 12-month low price of $0.82 and touched a high of $9.02 over the same period. Currently, 2.4 million shares have been traded, compared to an average intraday trading volume of 8.61 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -17.19%, 12.40%, and 37.40% respectively.

Institutional ownership of Arbutus Biopharma Corporation (NASDAQ: ABUS) shares accounts for 34.90% of the company’s 69.61M shares outstanding. Mutual fund holders own 33.86%, while other institutional holders and individual stakeholders account for 4.76% and 29.18% respectively.

It has a market capitalization of $270.20M and a beta (3y monthly) value of 3.10. The earnings-per-share (ttm) stands at -$2.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.76% over the week and 15.05% over the month.

Analysts forecast that Arbutus Biopharma Corporation (ABUS) will achieve an EPS of -$0.22 for the current quarter, -$0.22 for the next quarter and -$0.77 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was $0.01 a year ago. Earnings per share for the fiscal year are expected to decrease by -137.80%, and 16.30% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Arbutus Biopharma Corporation (ABUS) as a “Moderate Buy” at a consensus score of 2.30. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 1 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the ABUS, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on July 27, 2020, with the firm’s price target at $10-$8. Robert W. Baird coverage for the Arbutus Biopharma Corporation (ABUS) stock in a research note released on July 24, 2020 offered a Neutral rating with a price target of. Wedbush was of a view on May 19, 2020 that the stock is Outperform, while Chardan Capital Markets gave the stock Buy rating on March 06, 2020, issuing a price target of $5. Robert W. Baird on their part issued Outperform rating on February 20, 2020.


Please enter your comment!
Please enter your name here